Top Markets
Coin of the day
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
주식 순위 #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
주가
$0.051239
마지막 동기화: 2025-11-24
시가총액
$1.38M
변동 (1일)
-4.48%
변동 (1년)
-54.57%
국가
NO
거래 BerGenBio ASA (BGBIO)

카테고리

BerGenBio ASA (BGBIO)의 주가 이력
최고 종가: $0.08 (2025-11-01 기준)

최저 종가: $45.81 (2017-04-01 기준)
BerGenBio ASA의 주가 이력 (2017 ~ 2026)
연간 주가 성과
연도 성과
2026 (TTM) 36.04%
2025 -90.51%
2024 -63.90%
2023 -73.76%
2022 -63.83%
2021 -44.23%
2020 73.06%
2019 -30.98%
2018 -3.30%
2017 0.00%
유사 기업 또는 경쟁사의 주가
회사 주가 변동률 1년% 국가
$505.24 28.63%
US
$846.09 29.41%
NL
$731.69 6.47%
CH
$1.07K -6.40%
KR
$251.82 11.75%
BE